<DOC>
	<DOCNO>NCT00468208</DOCNO>
	<brief_summary>Wegener 's granulomatosis ( WG ) rare disease cause inflammation blood vessel , vasculitis . It may involve many different part body , typically affect upper low respiratory tract kidney . The purpose study determine safety effectiveness medication abatacept treat adult mild relapse WG .</brief_summary>
	<brief_title>Abatacept Treating Adults With Mild Relapsing Wegener 's Granulomatosis</brief_title>
	<detailed_description>Current standard treatment WG involve various medication base disease severity . Unfortunately , 50 % people experience relapse remission , place risk additional organ damage medication toxicity . To prevent , safer effective treatment mild relapse need . Several study show activated T cell , type white blood cell important regulating immune response , play role WG . Abatacept , immunoglobulin-based medication approve FDA treat rheumatoid arthritis , act prevent T-cell activation may useful treat mild relapse WG . The purpose study determine safety effectiveness abatacept treat adult mild relapse WG . Participants receive abatacept intravenously study visit Days 1 , 15 , 29 , month thereafter . A participant 's abatacept dose base body weight remain throughout study . Participants receive maintenance immunosuppressive medication consist methotrexate , azathioprine , mycophenolate mofetil time enrollment remain medication without dosage increase reduction . Eligible participant may prednisone 15mg daily time relapse . Following development relapse , participant may treat prednisone 30mg daily necessary , must back dose prior relapse Month 2 . All study visit include medication review , physical exam , blood urine collection , questionnaire . A chest x-ray , compute tomography ( CT ) scan chest sinus , lung function test occur study visit . Participants whose symptom improve Month 2 take abatacept . Any participant undergo early termination , common closing , undergo three follow-up study visit 1 , 3 , 6 month end treatment .</detailed_description>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis WG , meet least 2 5 modified American College Rheumatology ( ACR ) criterion . More information criterion find protocol . Relapse WG within past 28 day disease activity confine one follow site symptoms/signs nature usual treatment would consist reinstitution increase GC prednisone 30mg daily and/or increase addition second immunosuppressive agent CYC ( specific information criterion find protocol ) : 1 . Sinonasal disease 2 . Oral mucosa ulceration 3 . Skin disease 4 . Musculoskeletal disease 5 . Pulmonary parenchymal disease 6 . Mild ocular disease 7 . Subglottic inflammation without significant stenosis 8 . Otic disease 9 . Breast involvement 10 . Urogenital involvement 11 . Other mild disease Age 15 year old Willing able undergo treatment attend followup visit Willing use effective form contraception throughout study Disease involvement meet criterion mild disease . More information criterion find protocol . Disease activity would usually treat first cyclophosphamide Presence disease activity investigator would normally treat participant prednisone 30 mg daily . Receiving cyclophosphamide study entry Treatment prednisone dose 15 mg daily time relapse . Subjects eligible prednisone initiate dose increased period relapse study enrollment provide prednisone dose 15 mg daily less time relapse occur , prednisone dosage increase high 30 mg daily follow recognition relapse , dosage increase make 28 day prior enrollment . Active infection HIV infect , hepatitis C virus infect , positive hepatitis B Unable follow study participation Cytopenia , define platelet count less 80,000/mm3 , absolute neutrophil count less 1500/mm3 , OR hematocrit le 20 % Kidney insufficiency Use illegal drug Any uncontrolled disease would prevent participation History cancer . More information criterion find protocol . Received investigational medication procedure within 30 day study entry Received live vaccine within 4 week study entry Positive tuberculin skin test . More information criterion find protocol . Tuberculosis indicate radiographic evidence Past treatment rituximab within past 12 month , past treatment rituximab 12 month ago B lymphocyte count return normal Certain disease . More information criterion find protocol . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>Relapse</keyword>
	<keyword>Wegener 's</keyword>
	<keyword>Treatment</keyword>
</DOC>